Cellarity was created by Flagship Pioneering and launched in December 2019. Cellarity’s journey began with brainstorming sessions between Flagship Pioneering Founder and CEO Noubar Afeyan, Partner Avak Kahvejian and Senior Associate Nick Plugis. The team recognized that powerful new biological and computational technologies exist to perturb and quantify virtually any cellular or molecular component. They also envisioned that these technologies could generate the data necessary to unravel biological complexity. From this strategy, the three founders aspired to produce drug candidates with improved translatability throughout the discovery and development process.
Thus, Cellarity was created—a first-of-its-kind therapeutics company—to develop medicines by studying and altering the cellular signatures of disease. With the unique ability to create drugs through the lens of the entire cell, Cellarity strives to increase the success of drug discovery and address the presently intractable diseases for which casual targets are either undruggable or unknown.
About Flagship Pioneering
Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in more than $100 billion in aggregate value. To date, Flagship has deployed over $2.9 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including Moderna, which created and developed a Covid vaccine in record time, helping to address an unexpected global pandemic.